- Portfolio Prep for Next Week: 'Don't Get Crazy'
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Surprising Options Trades in TiVo Shares
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
MOST SHARED
- Tiger Woods Out of Hospital After Accident
- The Good Entrepreneur Winner
- Get Paid Six Figures to Wear a T-Shirt?
- Halftime Report: Dubai - First Ripple Of Larger Crisis?
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Spooks Investors But May Bring Buying Opportunity
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Dubai's Debt Woes Signal New Era for Creditors
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Fed Audit Would Hurt Economic Prospects: Bernanke
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Tiger Woods Out of Hospital After Accident
RSS FEED
CNBC Stock Blog
Text Size 
Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.
“They were out of favor over the last three or four years, even before the current market slowdown, which has made them even cheaper,” he said.
Recommendations:
Burnick recommends GlaxoSmithKline [GSK
Loading...
()
] — which beat earnings estimates Wednesday — Novartis [NVS
Loading...
()
] and Johnson & Johnson [JNJ
Loading...
()
].
“It’s [Johnson & Johnson] considered the Rolls-Royce of the industry,” he said. “That’s the bluest of the blue chips.”
Merck [MRK
Loading...
()
], for instance, is a good blue-chip name, but it still has “restructuring to do and of course the jury is always out on that, having steep job cuts,” said Burnick.
Pfizer [PFE
Loading...
()
], meanwhile, is a solid alternative to Merck.
“Pfizer is about as cheap as you can get,” he said. “It’s trading at about seven times this year’s earnings; it has a very nice dividend yield.”
Investor Caveat:
Despite attractive prices in the pharmaceutical sector, Vince Farrell of Soleil Securities recommends investors exercise caution.
“I think a degree of caution is called for here only because you have patent expirations and you have the threat—call it a threat of a new [presidential] administration renewing their focus on pharmaceutical costs,” said Farrell, a CNBC contributor.
Farrell is bullish on Pfizer and Johnson & Johnson.
Disclosures:
Disclosure information was not available for Burnick or his firm.
Farrell is a regular CNBC contributor.
Data is a real-time snapshot *Data is delayed at least 15 minutes